Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.

Chan, Anthony K; Alamelu, Jayanthi; Barnes, Chris; Chuansumrit, Ampaiwan; Garly, May-Lill; Meldgaard, Rikke Medom; Young, Guy

Chan, Anthony K; Alamelu, Jayanthi; Barnes, Chris; Chuansumrit, Ampaiwan; Garly, May-Lill; Meldgaard, Rikke Medom; Young, Guy.

Afiliación

Chan AK; McMaster Children's Hospital/McMaster University Hamilton ON Canada.
Alamelu J; Evelina London Children's Hospital London UK.
Barnes C; The Royal Children's Hospital Melbourne VIC Australia.
Chuansumrit A; Ramathibodi Hospital Mahidol University Bangkok Thailand.
Garly ML; Novo Nordisk A/S Søborg Denmark.
Meldgaard RM; Novo Nordisk A/S Søborg Denmark.
Young G; Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles CA USA.

Res Pract Thromb Haemost ; 4(7): 1101-1113, 2020 Oct.

Article en En | MEDLINE | ID: mdl-33134776

Palabras clave

factor IX; hemophilia B; nonacog beta pegol; previously untreated patients; prophylaxis; recombinant proteins

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Res Pract Thromb Haemost Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google